Clindamycin
/ Clindamycin, Acanya, Cabtreo, Cleocin, Clindagel, Clindamycin, Clindamycin /, Clinderm, Clindesse, Clindets, Duac, Onexton, Veltin, Xaciato, Ziana (clindamycin) is a small molecule pharmaceutical. Clindamycin was first approved as Cleocin hydrochloride on 1982-01-01. It is used to treat acne vulgaris, actinomycetales infections, bacterial infections, bacterial vaginosis, and bacteroides infections amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Cleocin, Clindagel, Clindesse, Xaciato (generic drugs available since 1986-04-07, discontinued: Cleocin, Evoclin)
CombinationsAcanya, Cabtreo, Duac, Onexton, Veltin, Ziana (generic drugs available since 1986-04-07, discontinued: Benzaclin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Adapalene
+
Benzoyl peroxide
+
Clindamycin phosphate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CABTREO | Bausch Health Companies | N-216632 RX | 2023-10-20 | 1 products, RLD, RS |
Benzoyl peroxide
+
Clindamycin phosphate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ONEXTON | Bausch Health Companies | N-050819 RX | 2014-11-24 | 1 products, RLD, RS |
| ACANYA | Bausch Health Companies | N-050819 RX | 2008-10-23 | 1 products, RLD, RS |
| DUAC | Stiefel Laboratories | N-050741 RX | 2002-08-26 | 1 products, RLD |
Show 1 discontinued
Clindamycin hydrochloride
Clindamycin phosphate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% | APP Pharmaceuticals | N-050635 RX | 1989-12-22 | 1 products, RLD, RS |
| CLINDAGEL | Bausch Health Companies | N-050782 RX | 2000-11-27 | 1 products, RLD, RS |
| CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE | Baxter | N-208083 RX | 2017-04-20 | 3 products, RLD, RS |
| XACIATO | Organon | N-215650 RX | 2021-12-07 | 1 products, RLD, RS |
| CLINDESSE | Padagis | N-050793 RX | 2004-11-30 | 1 products, RLD, RS |
| CLEOCIN PHOSPHATE | Mylan | N-050441 RX | 1982-01-01 | 1 products, RLD, RS |
| CLEOCIN T | Mylan | N-050600 RX | 1989-05-31 | 1 products, RLD, RS |
| CLEOCIN T | Mylan | N-050615 RX | 1987-01-07 | 1 products, RLD, RS |
| CLEOCIN | Mylan | N-050680 RX | 1998-03-02 | 1 products, RLD, RS |
| CLEOCIN | Mylan | N-050767 RX | 1999-08-13 | 1 products, RLD, RS |
Show 7 discontinued
Clindamycin phosphate
+
Tretinoin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VELTIN | Almirall | N-050803 RX | 2010-07-16 | 1 products, RLD, RS |
| ZIANA | Bausch Health Companies | N-050802 RX | 2006-11-07 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| acanya | New Drug Application | 2020-09-30 |
| adapalene 0.1% / benzoyl peroxide 2.5% / clindamycin 1% | unapproved drug other | 2020-06-03 |
| adapalene 0.3% / benzoyl peroxide 2.5% / clindamycin 1% | unapproved drug other | 2020-06-03 |
| benzaclin | New Drug Application | 2017-02-16 |
| benzoyl peroxide 2.5% / clindamycin 1% / niacinamide 2% / tretinoin 0.025% | unapproved drug other | 2019-05-22 |
| benzoyl peroxide 2.5% / clindamycin 1% / niacinamide 4% | unapproved drug other | 2019-04-23 |
| benzoyl peroxide 2.5%, clindamycin phosphate 1%, niacinamide 2% / tretinoin 0.05% | unapproved drug other | 2019-05-03 |
| benzoyl peroxide 5% / clindamycin 1% / niacinamide 2% / spironolactone 2% | unapproved drug other | 2019-05-10 |
| benzoyl peroxide 5% / clindamycin 1% / niacinamide 2% / spironolactone 2% / tretinoin 0.025% | unapproved drug other | 2019-05-03 |
| benzoyl peroxide 5% / clindamycin 1% / niacinamide 2% / spironolactone 2% / tretinoin 0.05% | unapproved drug other | 2019-05-02 |
Show 50 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
CLINDAMYCIN PHOSPHATE, XACIATO, ORGANON LLC | |||
| 2029-12-07 | GAIN | ||
| 2024-12-07 | NP | ||
ADAPALENE / BENZOYL PEROXIDE / CLINDAMYCIN PHOSPHATE, CABTREO, BAUSCH | |||
| 2026-10-20 | NP | ||
BENZOYL PEROXIDE / CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, TARO | |||
| 2024-03-30 | PC | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Adapalene / Benzoyl Peroxide / Clindamycin Phosphate, Cabtreo, Bausch | |||
| 11389467 | 2040-12-28 | DP | U-3713 |
| 8288434 | 2029-08-05 | DP | U-124, U-134, U-818, U-916, U-921, U-1033, U-3713 |
| 9561208 | 2029-06-03 | DP | U-916, U-3713 |
| 10220049 | 2029-06-03 | DP | U-916, U-3713 |
| 10624918 | 2029-06-03 | U-916, U-3713 | |
| Clindamycin Phosphate, Xaciato, Organon Llc | |||
| 11129896 | 2036-09-22 | U-3293 | |
| Benzoyl Peroxide / Clindamycin Phosphate, Acanya, Bausch | |||
| 8663699 | 2029-06-03 | U-124 | |
| 8895070 | 2029-06-03 | U-124 | |
| 9078870 | 2029-06-03 | DP | |
| 9504704 | 2029-06-03 | DP | U-124, U-134, U-818, U-916 |
| 10137142 | 2029-06-03 | DP | U-916 |
| Clindamycin Phosphate, Clindesse, Padagis Us | |||
| 9789057 | 2026-12-02 | DP | U-137 |
| Clindamycin Phosphate, Evoclin, Mylan | |||
| 7141237 | 2024-02-03 | DP | |
| 7374747 | 2024-01-23 | DP | U-921 |
ATC Codes
D: Dermatologicals
— D10: Anti-acne preparations
— D10A: Anti-acne preparations for topical use
— D10AF: Antiinfectives for treatment of acne
— D10AF01: Clindamycin
— D10AF51: Clindamycin, combinations
G: Genito urinary system and sex hormones
— G01: Gynecological antiinfectives and antiseptics
— G01A: Antiinfectives and antiseptics, excl. combinations with corticosteroids
— G01AA: Antibiotics, gynecological
— G01AA10: Clindamycin
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01F: Macrolides, lincosamides and streptogramins
— J01FF: Lincosamides
— J01FF01: Clindamycin
HCPCS
Code | Description |
|---|---|
| S0077 | Injection, clindamycin phosphate, 300 mg |
Clinical
Clinical Trials
293 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acne vulgaris | D000152 | EFO_0003894 | L70 | 14 | 5 | 20 | 23 | 6 | 65 |
| Bacterial vaginosis | D016585 | EFO_0003932 | — | 1 | 1 | 5 | 5 | 4 | 16 |
| Surgical wound infection | D013530 | — | — | 1 | 1 | 2 | 2 | 3 | 9 |
| Bacterial infections | D001424 | — | A49 | 2 | — | 2 | 1 | 2 | 7 |
| Staphylococcal infections | D013203 | — | A49.01 | — | 2 | 2 | 3 | 1 | 7 |
| Infections | D007239 | EFO_0000544 | — | 2 | 1 | 2 | 1 | 1 | 6 |
| Wound infection | D014946 | — | — | — | — | — | 5 | 1 | 6 |
| Abscess | D000038 | EFO_0003030 | — | — | — | — | 1 | 3 | 4 |
| Pneumocystis pneumonia | D011020 | EFO_0007448 | B59 | — | — | 1 | 1 | 2 | 4 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | — | 2 | 1 | 3 |
Show 33 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 1 | 4 | 2 | — | — | 7 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 1 | — | 3 | 4 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | — | 2 | 3 |
| Colorectal neoplasms | D015179 | — | — | — | 2 | 1 | — | — | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 1 | — | 2 | 3 |
| Vaginitis | D014627 | EFO_0005757 | N76 | 1 | — | 2 | — | — | 3 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | 1 | — | 1 | 2 |
| Methicillin-resistant staphylococcus aureus | D055624 | — | — | — | — | 2 | — | — | 2 |
| Bacterial skin diseases | D017192 | — | — | — | — | 1 | — | 1 | 2 |
| Hydrocephalus | D006849 | HP_0000238 | G91 | — | — | 1 | — | 1 | 2 |
Show 29 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Appendicitis | D001064 | EFO_0007149 | K37 | — | 1 | — | — | 2 | 3 |
| Cerebral toxoplasmosis | D016781 | EFO_0007200 | B58.2 | — | 1 | — | — | 2 | 3 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | 1 | — | — | — | 2 |
| Exanthema | D005076 | HP_0000988 | — | — | 2 | — | — | — | 2 |
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
| Head and neck neoplasms | D006258 | — | — | — | 1 | — | — | — | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | 1 | — | — | — | 1 |
| Abdominal abscess | D018784 | EFO_1001753 | — | — | 1 | — | — | — | 1 |
| Actinic keratosis | D055623 | — | L57.0 | — | 1 | — | — | — | 1 |
| Colonic neoplasms | D003110 | — | C18 | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | 1 | 2 |
| Postoperative pain | D010149 | — | G89.18 | 1 | — | — | — | 1 | 2 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | 1 | — | — | — | 1 | 2 |
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Jaw fractures | D007572 | — | — | 1 | — | — | — | — | 1 |
| Endometriosis | D004715 | EFO_0001065 | N80 | 1 | — | — | — | — | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bisphosphonate-associated osteonecrosis of the jaw | D059266 | — | — | — | — | — | — | 2 | 2 |
| Peritonsillar abscess | D000039 | EFO_0007429 | J36 | — | — | — | — | 2 | 2 |
| Hidradenitis suppurativa | D017497 | — | L73.2 | — | — | — | — | 2 | 2 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | — | 1 | 1 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 1 | 1 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 1 | 1 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | — | — | — | 1 | 1 |
| Mucocutaneous lymph node syndrome | D009080 | EFO_0004246 | M30.3 | — | — | — | — | 1 | 1 |
| Hyperaldosteronism | D006929 | HP_0011736 | E26 | — | — | — | — | 1 | 1 |
Show 38 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Clindamycin |
| INN | clindamycin |
| Description | Clindamycin is a lincosamide antibiotic medication used for the treatment of a number of bacterial infections, including osteomyelitis (bone) or joint infections, pelvic inflammatory disease, strep throat, pneumonia, acute otitis media (middle ear infections), and endocarditis. It can also be used to treat acne, and some cases of methicillin-resistant Staphylococcus aureus (MRSA). In combination with quinine, it can be used to treat malaria. It is available by mouth, by injection into a vein, and as a cream or a gel to be applied to the skin or in the vagina.
|
| Classification | Small molecule |
| Drug class | antibiotics (Streptomyces strain) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1 |
Identifiers
| PDB | — |
| CAS-ID | 18323-44-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1753 |
| ChEBI ID | — |
| PubChem CID | 446598 |
| DrugBank | DB01190 |
| UNII ID | 3U02EL437C (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Cleocin – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Clindamycin
+
Benzoyl peroxide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Clindamycin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Clindamycin
+
Tretinoin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 39,762 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cleocin hydrochloride, Cleocin pediatric, Cleocin phosphate, Cleocin phosphate cleocin phosphate (0009-6582) (standalone), Clindamycin, Clindamycin hcl, Clindamycin hydrochloride, Clindamycin hydrochloride clindamycin hydrochloride, Clindamycin palmitate hydrochloride, Clindamycin palmitate hydrochloride (pediatric)
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
17,306 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use